11d
Hosted on MSNSage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/YSage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...
Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...
Paul Matteis; Analyst; Stifel, Nicolaus & Company, Inc. Good afternoon. Welcome to Sage Therapeutics' fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions) This ...
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results